Efficacy and Safety of Dupilumab in the Treatment of Severe Asthma Insufficiently Controlled by Standard Therapy – Current Clinical Practice Data
If severe bronchial asthma with type 2 inflammation is insufficiently controlled by combined maintenance therapy, dupilumab – a recombinant monoclonal antibody inhibiting the signaling pathway of interleukins 4 and 13 – can be added. What is its efficacy in clinical practice? We summarize findings from 3 recent retrospective studies.
Early Efficacy of Dupilumab in the Treatment of Severe Asthma
A total of 12 patients (median age 64 years; 58% male) with severe asthma bronchiale insufficiently controlled by standard therapy were included in the Italian study (1). All had eosinophilia > 150 cells/ml and/or exhaled nitric oxide (FeNO) > 25 ppb in the last year. These patients were administered dupilumab subcutaneously in a loading dose of 400 mg and subsequently in a maintenance dose of 200 mg every 14 days.
After 3 months of therapy, significant improvement in disease control was observed. The asthma control test (ACT) score increased from 13.25 to 19.17 points (p < 0.01), relative forced expiratory volume in one second (FEV1%) from 62.58 to 71.00% (p < 0.01), and FeNO decreased from 32 to 19 ppb (p < 0.05). Lab results showed a numerical increase in eosinophils (from 280 to 350 cells/ml; p = 0.52) in blood. The increase in eosinophils was not statistically significant and had no clinical impact. A significant clinical difference (MCID) in FEV1% was achieved in 4 patients (33%), and in ACT in 8 patients (67%).
Efficacy of Dupilumab in Patients Previously Treated with Biological Therapy
The Austrian study (2) included a total of 13 patients (average age 47 years; 69% male). 85% of them had previously been treated with monoclonal antibodies (anti-IgE or anti-IL-5/IL-5R) without sufficient effect. Patients used dupilumab in the standard dosing regimen mentioned above.
After 2 weeks of therapy, the asthma control according to the ACQ-6 questionnaire improved by 0.57 points (p = 0.014) and after 4 weeks according to the ACT test by 3.91 points (p = 0.024). Both improvements were both statistically and clinically significant and maintained after 3 months of therapy. Statistically and clinically significant increases in forced expiratory volume in one second (FEV1) were observed after 4 weeks and 3 months from the start of therapy, increasing by 220 ml (p = 0.041) and 229 ml (p = 0.006), respectively.
During the therapy, no hypereosinophilia or severe treatment-related adverse events were reported. A total of 3 patients (23%) were concurrently using oral corticosteroids, and all could reduce their dose by at least 50% after 3 months due to dupilumab.
Efficacy and Safety of Dupilumab in Patients with Severe Asthma
The Dutch study (3) included a total of 148 patients with severe asthma insufficiently controlled by standard therapy between January 2019 and December 2020 (median age 52.5 years; 38.5% male). Patients again used dupilumab according to the standard dosing regimen.
After 12 months of therapy, the annual frequency of exacerbations decreased from 4.0 to 1.0 (p < 0.001), with 46% of patients being exacerbation-free for 12 months. This corresponded to improved asthma control according to the ACQ-5 questionnaire from 3.0 to 1.8 points after 6 months, and to 1.4 points after 12 months of therapy (p < 0.001). The necessity to use oral corticosteroids in maintenance therapy decreased from 39.9% of patients to 20.3% after 6 months and 14.9% after 12 months of therapy (p < 0.001). Significant improvements in FEV1 from 2.21 to 2.50 liters after 6 months and to 2.51 liters after 12 months of therapy (p < 0.001) were also observed. The best results overall were observed in the subgroup with marked eosinophilia (i.e., ≥ 300/µl) or a high FeNO (i.e., ≥ 50 ppb).
Treatment-related adverse events were reported in 45.3% of patients (n = 67). The most common issues were headaches, flu-like symptoms, eye complaints, and injection site reactions.
Summary and Discussion
According to the mentioned studies, dupilumab in patients with insufficiently controlled severe asthma early improves asthma control, already within 2 weeks to 3 months. Lung function (increase in FEV1) and FeNO improve and patients become less dependent on oral corticosteroids during therapy. Dupilumab is also suitable for patients who insufficiently responded to anti-IL5/IL-5R or anti-IgE biological treatments. However, the first two cited studies are limited by the small number of participants and larger prospective studies with longer follow-up periods will be necessary in the future.
(mafi)
Sources:
1. Carpagnano G. E., Scioscia G., Buonamico E. et al. Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management. Multidiscip Respir Med 2022; 17 (1): 797, doi: 10.4081/mrm.2022.797.
2. Renner A., Marth K., Patocka K. et al. Dupilumab rapidly improves asthma control in predominantly anti-IL5/IL5R pretreated Austrian real-life severe asthmatics. Immun Inflamm Dis 2021; 9 (3): 624–627, doi: 10.1002/iid3.434.
3. Thelen J. C., van Zelst C. M., van Brummelen S. E. et al. Efficacy and safety of dupilumab as add-on therapy for patients with severe asthma: a real-world Dutch cohort study. Respir Med 2023; 206: 107058, doi: 10.1016/j.rmed.2022.107058.
Did you like this article? Would you like to comment on it? Write to us. We are interested in your opinion. We will not publish it, but we will gladly answer you.